Huntington's disease, behavioral disturbances, and kynurenines: Preclinical findings and therapeutic perspectives

Biological Psychiatry

Volumn 39, Issue 12, 1996, Pages 1061-1063

  Vécsei, László ^a   Beal, M Flint ^b  

^a UNIVERSITY OF SZEGED   (Hungary)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Behavior; Huntington's disease; Kynurenine; Quinolinic acid

Indexed keywords

KYNURENIC ACID; KYNURENINE; PROBENECID;

ARTICLE; BEHAVIOR DISORDER; HUMAN; HUNTINGTON CHOREA; PRIORITY JOURNAL;

EID: 0342592253     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-3223(95)00377-0     Document Type: Article

References (29)

1. Beal MF, Marshall PE, Bird ED, Landis DMD, Martin JB (1985): Excitotoxin lesions do not mimic the alteration of somatostatin in Huntington's disease. Brain Res 361:135-145.
2. Beal MF, Kowall NW, Ellison DW, Mazurek MF, Swartz KJ, Martin JB (1986): Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature 321:168-171.
3. Beal MF, Kowall NW, Swartz KJ, Ferrante RJ, Martin JB (1989): Differential sparing of somatostatin-neuropeptide Y and cholinergic neurons following striatal excitotoxin lesions. Synapse 31:38-47.
4. Beal MF, Matson WR, Swartz KJ, Gamache P, Bird ED (1990): Kynurenine pathway measurements in Huntington's disease striatum: Evidence for reduced formation of kynurenic acid. J Neurochem 55:1327-1339.
5. Beal MF (1994): Neurochemistry and toxin models in Huntington's disease. Curr Opin Neurol 7:542-547.
6. Coyle JT, Schwarcz R (1976): Lesion of striatal neurons with kainic acid provides a model for Huntington's chorea. Nature 263:244-246.
7. Folstein SE, Franz ML, Jensen BA, Chase GA, Folstein MF (1983a): Conduct disorder and affective disorder among the offspring of patients with Huntington's disease. Psychol Med 13:45-52.
8. Folstein SE, Abbott MH, Chase GA, Jensen BA, Folstein MF (1993b): The association of affective disorder with Huntington's disease in a case series and in families. Psychol Med 13:537-542.
9. Hantraye P, Riche D, Isacson O (1990): A primate model of Huntington's disease: Behavioral and anatomical studies of unilateral excitotoxic lesions of the caudate-putamen in the baboon. Exp Neurol 108:91-104.
10. Heidelberger C, Gulberg ME, Morgan AF, Lepkovsky S (1949): Tryptophan metabolism I: Concerning the mechanism of the mammalian conversation of tryptophan into kynurenine, kynurenic acid and nicotinic acid. J Biol Chem 179:143-150.
11. Köhler C, Schwarcz R (1983): Comparison of ibotenate and kainate neurotoxicity in rat brain. A histological study. Neuroscience 8:819-835.
12. Martin JB, Gusella JF (1986): Huntington's disease. Pathogenesis and management. N Engl J Med 315:1267-1276.
13. McGeer EG, McGeer PL (1976): Duplication of biochemical changes of Huntington's chorea by intrastriatal injection of glutamic and kainic acids. Nature 263:517-519.
14. Nozaki K, Beal MF (1992): Neuroprotective effects of L-kynurenine on hypoxia-ischemia and NMDA lesions in neonatal rats. J Cerebral Blood Flow Metabol 12:400-407.
15. Podolsky S, Leopold NA (1977): Abnormal glucose tolerance and arginine tolerance tests in Huntington's disease. Gerontology 23:55-63.
16. Sanberg PR, Calderon SF, Giordano M, Tew JM, Norman AB (1989): The quinolinic acid model of Huntington's disease: Locomotor abnormalities. Exp Neurol 105:45-53.
17. Schwarcz R, Whetsell WO, Mangano RM (1983): Quinolinic acid: An endogenous metabolite that produces axon-sparing lesion in rat brain. Science 219:316-318.
18. Schwarcz R, Foster HC, French ED, Whetsell WE, Köhler C (1984). Excitotoxic models of neurodegenerative disorders. Life Sci 35:19-32.
19. Stone TW, Connick JH (1985): Quinolinic acid and other kynurenines in the central nervous system. Neuroscience 15:597-617.
20. Stone TW (1993): Neuropharmacology of quinolinic and kynurenic acids. Pharmacol Rev 45:309-379.
21. Storey E, Cipolloni PB, Ferrante RJ, Kowall NW, Beal MF (1994): Movement disorder following excitotoxin lesions in primates. NeuroReport 5:1259-1261.
22. Vécsei L, Beal MF (1990a): Influence of kynurenine treatment on open-field activity, elevated plus maze, avoidance behaviors and seizures in rats. Pharmacol Biochem Behav 37:71-76.
23. Vécsei L, Beal MF (1990b): Intracerebroventricular injection of kynurenic acid, but not kynurenine, induces ataxia and stereotyped behavior in rats. Brain Res Bull 25:623-627.
24. Vécsei L, Beal MF (1991a): Comparative behavioral and neurochemical studies with striatal kainic acid or quinolinic acid lesioned rats. Pharmacol Biochem Behav 39:473-478.
25. Vécsei L, Beal MF (1991b): Comparative behavioral and pharmacological studies with centrally administered kynurenine and kynurenic acid in rats. Eur J Pharmacol 196:239-246.
26. Vécsei L, Beal MF (1992): Behavioral and pharmacological effects of centrally administered aminooxyacetic acid in rats. Eur J Pharmacol 220:259-262.
27. Vécsei L, Miller J, MacGarvey U, Beal MF (1992a): Kynurenine and probenecid inhibit pentylenetetrazol-and NMDLA-induced seizures and increase kynurenic acid concentrations in the brain. Brain Res Bull 28:233-238.
28. Vécsei L, Miller J, MacGarvey U, Beal MF (1992b): Effects of kynurenine and probenecid on plasma and brain tissue concentrations of kynurenic acid. Neurodegeneration 1:17-26.
29. Vécsei L, Freese A, Swartz KJ, Beal MF (1992c): Neurological Disorders: Novel Experimental and Therapeutic Strategies. Chichester: Ellis Horwood.